Survival Analysis and Prognosis for Patients with Serous and Mucinous Borderline Ovarian Tumors: 14-Year Experience from a Tertiary Center in Iran
The aim of this study was to determine the prognosis and survival for patients with borderlineovarian tumor (BOT). A retrospective review of 30 patients with serous andmucinous BOT treated at or referred to our institution was performed. Fifteenpatients (50%) had serous, and the others had mucinous BOT. About 86% of allpatients in both groups were in stage I of the disease. The recurrent disease occurredin 7% and 21% of serous and mucinous tumors, respectively. All recurrences,except one in mucinous tumors, were found in advance stage disease. After amean of 37 and 52 months follow-up, the overall survival was 100% and 93%, anddisease-free survival was 93% and 79% for serous and mucinous tumors,respectively. In this series, advanced stage was associated with poorprognosis. However, to obtain more accurate information further studies withnumber of patients and longer follow-up is recommended.
Morice P, Uzan C, Fauvet R, et al. Borderline ovarian tumour: pathological diagnostic dilemma and risk factors for invasive or lethal recurrence. Lancet Oncol 2012;13(3):e103-15.
Trope CG, Kaern J, Davidson B. Borderline ovarian tumours. Best Pract Res Clin Obstet Gynaecol 2012;26(3):325-36.
Al-Nafussi A. Ovarianepithelial tumours: common problems in diagnosis. Curr Diagnos Pathol 2004;10(6):473-99.
Seidman JD, Soslow RA, Vang R, et al. Borderline ovarian tumors: Diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images. Hum Pathol 2004;35(8):918-33.
Bagade P, Edmondson R, Nayar A. Management of borderline ovarian tumours. Obstet Gynaecol 2012;14(2):115-20.
Bouchardy C, Fernandez S, Merglen A, et al. Increased risk of second cancer among patients with ovarian borderline tumors. Gynecol Oncol 2008;109(2):210-4.
Parker RL, Clement PB, Chercover DJ, et al. Early recurrence of ovarian serous borderline tumor as highgrade carcinoma: a report of two cases. Int J Gynecol Pathol 2004;23(3):265-72.
Slomovitz BM, Caputo TA, Gretz HF 3rd et al. A comparative analysis of 57 serous borderline tumors with and without a noninvasive micropapillary component. Am J Surg Pathol 2002;26(5):592-600.
Bell KA, Smith Sehdev AE, Kurman RJ. Refined diagnostic criteria for implants associated with ovarian atypical proliferative serous tumors (borderline) and micropapillary serous carcinomas. Am J Surg Pathol 2001;25(4):419-32.
Tinelli R, Tinelli A, Tinelli FG, et al. Conservative surgery for borderline ovarian tumors: a review. Gynecol Oncoln 2006;100(1):185-91.
Acs G. Serous and mucinous borderline (low malignant potential) tumors of the ovary. Am J Clin Pathol 2005;123(Suppl):S13-57.
Priya C, Kumar S, Kumar L. Borderline ovarian tumours: An update. Indian J Med Paediatr Oncol 2008;29(2):19-27.
Morice P, Camatte S, Rey A, et al. Prognostic factors for patients with advanced stage serous borderline tumours of the ovary. Ann Oncol 2003;14(4):592-8.
Lalwani N, Shanbhogue AK, Vikram R, et al. Current update on borderline ovarian neoplasms. AJR Am J Roentgenol 2010;194(2):330-6.
Longacre TA, McKenney JK, Tazelaar HD, et al. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with longterm (> or =5-year) follow-up. Am J Surg Pathol 2005;29(6):707-23.
Prat J, De Nictolis M. Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including
with a micropapillary pattern and 20 with microinvasion. Am J Surg Pathol 2002;26(9):1111-28.
Diebold J, Amann G, Seemüller F, et al. Diagnostic and molecular genetic pathology of serous borderline tumors of the ovary. Curr Diag Pathol 2004;10(4):318-25.
Shappell HW, Riopel MA, Smith Sehdev AE, et al. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas. Am J Surg Pathol 2002;26(12):1529-41.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.